Article | 03.11.2026
Blog and news
topic :
category :
status :
Article | 28.10.2026
2026 EASL-EASD-EASO Guidance: FibroScan® Now Integrated into MASH Treatment Eligibility and Monitoring
Press Release | 15.10.2026
Echosens and Gastro Health Partner to Advance Non-Invasive Liver Health Assessment and Metabolic Disease Management
Article | 12.10.2026
New Baveno VIII Guidelines Reinforce FibroScan® and VCTE® for Portal Hypertension Assessment
Webinar | 14.09.2026
Baveno VIII in Practice: How Non-Invasive Tests Are Reshaping Portal Hypertension Management
Article | 14.08.2026
CAP VS Abdominal Ultrasound
Article | 14.08.2026
How can liver fibrosis be assessed without a biopsy? The role of noninvasive tests and controlled-vibration pulse elastography
Article | 14.08.2026
MASLD vs MASH: what are the differences?
Article | 06.08.2026
Fierce Healthcare: Not All Noninvasive Imaging Technologies Are Evaluated the Same by Payers
Press Release | 16.07.2026
Echosens Shares BlueCross BlueShield of Tennessee Medical Policy Update Clarifying Coverage for FibroScan® and Other Noninvasive Elastography Technologies
Article | 01.07.2026
Appropriate Coding and Billing for FibroScan®
Webinar | 15.06.2026
FibroScan® Guided VCTE® : Best Practice Review and Clinical Insights
Webinar | 15.06.2026
Multidisciplinary management of MASLD–MASH: bridging diabetology and hepatology
Webinar | 15.06.2026
How to Build & Operationalize a Successful Liver Program with FibroScan®
Press Release | 02.06.2026